Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300284 · ClinicalTrials.gov registry record
Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer
A clinical trial of Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 186
- Enrollment target
- 5
- Study locations
NCT03300284: Completed study of Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03300284 is a study of Thyroid Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 186 participants, below the 278-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (33% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03300284, a study of Thyroid Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to understand the decision-making process regarding management choice in low-risk papillary thyroid cancer.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaires
Study Locations (5)
New York
- MAIMONIDES MEDICAL CENTER (Data collection only) - Brooklyn
- Memorial Sloan Kettering Cancer Center - New York
Connecticut
- Hartford Healthcare (Data Collection) - Hartford
New Jersey
- Memorial Sloan Kettering Monmouth (Consent and Follow up) - Middletown
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2017-08-07 |
| Est. Completion | 2023-07-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03300284
The ClinicalTrials.gov registry entry for NCT03300284 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 278-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (33% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.
NCT03300284 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Connecticut, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03300284 about?
NCT03300284 is a clinical study titled "Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer". This study is being done to understand the decision-making process regarding management choice in low-risk papillary thyroid cancer.
What is the current status of trial NCT03300284?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2017-08-07. Estimated completion is 2023-07-13.
What conditions does trial NCT03300284 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT03300284?
The interventions under investigation include: Questionnaires (BEHAVIORAL).
Who is sponsoring clinical trial NCT03300284?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03300284 being conducted?
This trial has 5 study locations across Connecticut, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.